五种免疫检测法筛查既往登革热感染的准确性及疫苗效力再评估
该回顾性分析基于CYD14和CYD15三期试验免疫原性子集,用五种商用免疫检测法判定基线登革热血清状态,并评估CYD-TDV在检测阳性者中的疫苗效力。结果显示各检测法特异性高但敏感性差异大,ELISA敏感性高于RDT,阳性者中疫苗效力普遍较高。
要点
- 五种免疫检测法特异性均高,但敏感性差异明显,ELISA优于RDT。
- 免疫检测阳性者中,CYD-TDV对症状性登革热的疫苗效力较高。
- 这些检测法可用于接种前筛查以辅助风险分层,直至更敏感便捷的检测出现。
核心结论
- 五种商用免疫检测法可用于CYD-TDV接种前筛查,作为风险分层工具,直至更敏感便捷的检测可用。
研究设计与样本
- 回顾性分析三期CYD14和CYD15疫苗效力试验的免疫原性子集,纳入2011-12年亚太五国和拉美五国2-16岁儿童。
- 样本来自至少接种一剂研究药物且有基线样本的参与者,共3967份基线样本可用。
主要发现
- 检测阳性者中,五种免疫检测法对应的针对症状性病毒学确诊登革热的疫苗效力均较高。
- 针对住院病毒学确诊登革热的疫苗效力在五种检测法中亦较高。
- 针对重症病毒学确诊登革热的疫苗效力在五种检测法中多数较高但置信区间宽。
临床怎么用
- 在CYD-TDV接种前,可用这些免疫检测法筛查既往登革热感染以辅助风险分层。
- 选择检测法时需权衡敏感性差异,ELISA敏感性较高但RDT便捷性可能更优。
局限性
- 本研究为回顾性分析,基于三期试验的免疫原性子集。
- 部分疫苗效力估计的95%CI较宽,尤其针对重症登革热。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tetravalent dengue vaccine (CYD-TDV) has been shown to provide protection against dengue disease over 5-year follow-up in participants with previous dengue infection, but increased the risk of dengue hospitalisation and severe dengue during long-term follow-up in those without previous dengue infection. WHO recommended pre-vaccination screening to identify those with previous dengue infection (ie, dengue seropositive) who would benefit from vaccination. We re-evaluated CYD-TDV efficacy in those identified as dengue seropositive using five commercially available immunoassays, and assessed immunoassay performance. METHODS: We included participants in the immunogenicity subsets of the phase 3 CYD14 (NCT01373281) and CYD15 (NCT01374516) CYD-TDV efficacy trials, which enrolled children aged 2-16 years in 2011-12 in five countries in the Asia-Pacific region (CYD14) and five Latin American countries (CYD15). Participants assessed had received at least one injection of study drug (CYD-TDV or placebo) and had baseline samples available. We tested baseline samples by IgG-based immunoassays to classify baseline dengue serostatus, using two ELISAs (EUROIMMUN and Panbio) and three rapid diagnostic tests (RDTs; TELL ME FAST, SD BIOLINE, and OnSite). Vaccine efficacy in preventing symptomatic, hospitalised, and severe virologically confirmed dengue was determined for participants who tested positive by each immunoassay. The specificity and sensitivity of each immunoassay was determined as percentage negative and positive agreement compared with the reference algorithm, which used dengue plaque reduction neutralisation test with 50% and 90% cutoffs and non-structural protein 1 IgG ELISA results to assign baseline serostatus. FINDINGS: Samples were available for 3967 participants, 2735 (69·0%) of whom were classified as seropositive by the reference algorithm. Vaccine efficacy against symptomatic virologically confirmed dengue in immunoassay-positive participants was high across all five immunoassays (EUROIMMUN ELISA 88·2% [95% CI 77·3 to 93·9], Panbio ELISA 87·6% [76·7 to 93·4], TELL ME FAST RDT 88·8% [67·0 to 96·2], SD BIOLINE RDT 82·8% [66·9 to 91·1], and OnSite RDT 89·7% [64·6 to 97·0]), as was vaccine efficacy against hospitalised virologically confirmed dengue (EUROIMMUN-ELISA 72·8% [38·9 to 87·9], Panbio ELISA 77·5% [52·8 to 89·3], TELL ME FAST RDT 92·4% [37·8 to 99·1], SD BIOLINE RDT 87·2% [54·5 to 96·4], and OnSite RDT 73·7% [-5·1 to 93·4]) and severe virologically confirmed dengue (EUROIMMUN ELISA 86·9% [-16·8 to 98·5], Panbio ELISA 91·3% [27·6 to 99·0], TELL ME FAST RDT 100·0% [not estimable to 100·0%], SD BIOLINE RDT 89·4% [9·6 to 98·8], and OnSite RDT 73·4% [-193·7 to 97·6]). The immunoassays exhibited high specificity (≥98·8% for all immunoassays apart from SD BIOLINE RDT) but variable sensitivities, with higher sensitivities observed for the ELISAs (EUROIMMUN 89·2% [87·9 to 90·3] and Panbio 92·5 [91·4 to 93·5]) than the RDTs (TELL ME FAST 52·5% [50·6 to 54·4], SD BIOLINE 71·1% [69·3 to 72·8], and OnSite 47·6% [45·7 to 49·5]). INTERPRETATION: Our findings suggest that these immunoassays could be used for pre-vaccination screening for CYD-TDV as tools to assist risk stratification until more sensitive and convenient tests become available. FUNDING: Sanofi Pasteur.
引用
- DiazGranados CA, Bonaparte M, Wang H, et al. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. Lancet Infect Dis. 2020. PMID: 33212068. doi:10.1016/S1473-3099(20)30695-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。